ATXS - NASDAQ

Astria Therapeutics, Inc.

ATXS·NASDAQ

$12.58

+0.0000%

HealthcareBiotechnology

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$718.13M

EPS-1.6800

P/E Ratio-7.49

Earnings Date03/10/2026

atxs

Total Debt

Last Annual Value

5.35M

3-Year CAGR

145%

5-Year CAGR

19%

10-Year CAGR

Adjust for Inflation

Astria Therapeutics, Inc. Competitors Analysis of Total Debt

ATXS · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Astria Therapeutics, Inc. NASDAQ:ATXS	5.35M	153.4%	71.1%	-0.7%
Iovance Biotherapeutics, Inc. NASDAQ:IOVA	48.44M	-13.9%	-7.5%	N/A
Erasca, Inc. NASDAQ:ERAS	47.14M	-5.5%	20.2%	N/A
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	14.00K	-64.7%	N/A	N/A
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	596.00K	22.5%	N/A	N/A
Replimune Group, Inc. NASDAQ:REPL	76.17M	7.8%	18.0%	N/A
Arvinas, Inc. NASDAQ:ARVN	8.50M	38.5%	11.2%	34.0%
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	2.79M	89.9%	66.2%	N/A
Ginkgo Bioworks Holdings, Inc. NYSE:DNA	417.08M	20.3%	78.5%	N/A
MeiraGTx Holdings plc NASDAQ:MGTX	88.69M	-0.2%	30.2%	144.8%

Astria Therapeutics, Inc. Fair Value Envelope

ATXS · NASDAQ

Our analysis suggests that ATXS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.58, this represents a potential HIDDEN relative to our calculated worth for Astria Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $12.58

Related Guides

Blog Categories

Continue your ATXS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.